ClinicalTrials.gg
Not yet recruitingNCT07597564Updated May 20, 2026

Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation

A Phase 4 interventional study of Metoprolol (MET) and Sufentanil in General Anesthesia; Tracheal Intubation, sponsored by Fujian Provincial Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Fujian Provincial Hospital · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This randomized, double-blind, controlled clinical study will evaluate the effects of different dose combinations of intravenous metoprolol and sufentanil on cardiovascular responses during oral endotracheal intubation under general anesthesia.

Endotracheal intubation may cause transient increases in heart rate and blood pressure due to sympathetic stimulation. This study aims to determine whether metoprolol, in combination with different doses of sufentanil, can improve hemodynamic stability during and after intubation.

A total of 900 adult patients aged 18 to 65 years with American Society of Anesthesiologists physical status I or II who are scheduled for elective non-cardiac surgery under general anesthesia with endotracheal intubation will be enrolled. Participants will be randomly assigned to one of 30 groups according to the combination of metoprolol dose and sufentanil dose. Metoprolol doses include 0, 0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg, and sufentanil doses include 0.1, 0.2, 0.3, 0.4, and 0.5 mcg/kg.

All participants will receive standardized anesthetic induction and maintenance. Hemodynamic changes will be observed for 10 minutes after intubation. The main outcome is the success rate of hemodynamic stability within 0 to 10 minutes after intubation. Secondary outcomes include the incidence of hypotension, hypertension, bradycardia, and tachycardia.

02

Conditions studied

  • General Anesthesia; Tracheal Intubation
03

In context

Lead sponsor

Fujian Provincial Hospital is the lead sponsor of 41 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years.
  • physical status I or II.
  • Scheduled for elective non-cardiac surgery.
  • Planned general anaesthesia with endotracheal intubation.

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular or respiratory diseases, such as uncontrolled hypertension or bronchial asthma.
  • Current use of β-blockers.
  • History of chronic drug use or alcohol abuse.
  • Hepatic or renal impairment.
  • Known allergy to any study drug.
  • Anticipated difficult airway.
  • Any other condition that may affect the conduct of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
900 participants (estimated)

Study arms

  • Active comparator
    Metoprolol 0 mg/kg + Sufentanil 0.1 mcg/kg

    Drug: Sufentanil · Drug: Normal Saline (0.9% NaCl)

  • Active comparator
    Metoprolol 0 mg/kg + Sufentanil 0.2 mcg/kg

    Drug: Sufentanil · Drug: Normal Saline (0.9% NaCl)

  • Active comparator
    Metoprolol 0 mg/kg + Sufentanil 0.3 mcg/kg

    Drug: Sufentanil · Drug: Normal Saline (0.9% NaCl)

  • Active comparator
    Metoprolol 0 mg/kg + Sufentanil 0.4 mcg/kg

    Drug: Sufentanil · Drug: Normal Saline (0.9% NaCl)

  • Active comparator
    Metoprolol 0 mg/kg + Sufentanil 0.5 mcg/kg

    Drug: Sufentanil · Drug: Normal Saline (0.9% NaCl)

  • Experimental
    Metoprolol 0.1 mg/kg + Sufentanil 0.1 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.1 mg/kg + Sufentanil 0.2 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.1 mg/kg + Sufentanil 0.3 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.1 mg/kg + Sufentanil 0.4 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.1 mg/kg + Sufentanil 0.5 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.2 mg/kg + Sufentanil 0.1 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.2 mg/kg + Sufentanil 0.2 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.2 mg/kg + Sufentanil 0.3 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.2 mg/kg + Sufentanil 0.4 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.2 mg/kg + Sufentanil 0.5 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.3 mg/kg + Sufentanil 0.1 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.3 mg/kg + Sufentanil 0.2 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.3 mg/kg + Sufentanil 0.3 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.3 mg/kg + Sufentanil 0.4 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.3 mg/kg + Sufentanil 0.5 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.4 mg/kg + Sufentanil 0.1 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.4 mg/kg + Sufentanil 0.2 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.4 mg/kg + Sufentanil 0.3 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.4 mg/kg + Sufentanil 0.4 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.4 mg/kg + Sufentanil 0.5 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.5 mg/kg + Sufentanil 0.1 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.5 mg/kg + Sufentanil 0.2 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.5 mg/kg + Sufentanil 0.3 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.5 mg/kg + Sufentanil 0.4 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

  • Experimental
    Metoprolol 0.5 mg/kg + Sufentanil 0.5 mcg/kg

    Drug: Metoprolol (MET) · Drug: Sufentanil

Interventions

  • DrugMetoprololStudies of MetoprololMetoprolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metoprolol will be administered intravenously before anesthetic induction at the assigned dose of 0, 0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg. The study drug will be given through a dedicated intravenous catheter, and each participant will receive the dose according to the randomized treatment arm.

  • Sufentanil will be administered intravenously during anesthetic induction at the assigned dose of 0.1, 0.2, 0.3, 0.4, or 0.5 mcg/kg. Each participant will receive sufentanil in combination with the assigned metoprolol dose according to the randomized treatment arm.

  • DrugNormal Saline (0.9% NaCl)

    Normal saline (0.9% NaCl) will be administered intravenously before anesthetic induction as placebo in a volume matched to the metoprolol intervention. The study drug will be delivered through a dedicated intravenous catheter, and participants assigned to the placebo arm will receive a volume corresponding to the randomized dosing schedule used in the metoprolol groups.

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving hemodynamic stability after tracheal intubation

    Time frame: within 0-10 min after intubation

Secondary outcomes

  1. incidence of bradycardia

    Time frame: within 0-10 min after intubation

  2. incidence of tachycardia

    Time frame: within 0-10 min after intubation

  3. incidence of hypotension

    Time frame: within 0-10 min after intubation

  4. incidence of hypertension

    Time frame: within 0-10 min after intubation

Other outcomes

  1. adverse event

    Time frame: up to 24 hours postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 19, 2026
StartEst.
Jun 22, 2026
Primary completionEst.
May 22, 2027
CompletionEst.
May 22, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07597564
Lead sponsor
Fujian Provincial Hospital
Responsible party
Yanhua Guo (Associate Chief Physician, Fujian Provincial Hospital) — Principal investigator
First posted
May 19, 2026
Start date
Jun 22, 2026 (estimated)
Primary completion
May 22, 2027 (estimated)
Completion
May 22, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Yanhua Guo
Contact
guoyanhua19@126.com
+86-18050333902
Yanhua Guo
principal investigator · Fujian Provincial Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metoprolol · Sufentanil

Start the discussion